Galenicap uses a repeatable drug repurposing platform to redesign known compounds—optimizing formulation, delivery, or clinical positioning—to create differentiated therapies with improved efficacy, safety, or dosing convenience. By starting from drugs with established safety and validated mechanisms, the company de‑risks early development and accelerates progression to Phase I/II proof‑of‑concept, generating defensible IP and assets for licensing or partnership.
Funding
Funding not disclosed
Founders
Product
Problem
Developing new medicines from scratch involves high scientific risk, long timelines, and substantial capital requirements, leading to limited pipelines for addressing unmet medical needs. Existing drugs with known safety and mechanisms are often underutilized, leaving potential therapeutic improvements untapped.
Solution
Galenicap applies a repeatable drug repurposing platform that selects known compounds with validated biology and redesigns their formulation, delivery, or clinical positioning to create differentiated therapies. By leveraging established safety profiles, the company reduces early‑stage risk and accelerates progression to Phase I/II proof‑of‑concept. Each program targets a specific clinical gap—such as improved efficacy, safety, or dosing convenience—while generating defensible intellectual property. The portfolio is managed through a structured, multi‑disciplinary screening process that aligns target product profiles with market potential, enabling parallel advancement of multiple assets. Successful early‑stage assets are positioned for strategic licensing or partnership, providing a clear path to market and value creation.
Target Audience
Primary customers are pharmaceutical companies, specialty pharma partners, and biotech firms seeking licensed, clinically differentiated assets derived from known drugs, as well as investors focused on de‑risked, early‑stage therapeutic opportunities.
Features
- Systematic identification and redesign of known drug molecules to enhance efficacy, safety, or administration
- Formulation engineering (e.g., sustained‑release, oral extended‑release) to improve therapeutic consistency and patient adherence
- Early‑stage de‑risking by starting from compounds with established safety and validated mechanisms of action
- Multi‑disciplinary screening that integrates clinical, scientific, regulatory, IP, and commercial assessments against a defined Target Product Profile
- Generation of strong, defensible intellectual property around reformulated products and new indications
- Portfolio approach with eight active programs across CNS, oncology, infectious disease, and cardiovascular areas, each advanced to Phase I or II
- Structured pathway to strategic partnering or exit once early clinical proof is achieved